Publicaciones
-
Govindarajan R, Endres CJ, Whittington D, LeCluyse E, Pastor-Anglada M, Tse CM and Unadkat JD.
Expression and hepatobiliary transport characteristics of the concentrative and equilibrative nucleoside transporters in sandwich-cultured human hepatocytes.
AM J PHYSIOL-GASTR L . 295(3): . Nº de citas: 59
-
Perez-Torras S, García-Manteiga J, Mercadé E, Casado FJ, Carbó N, Pastor-Anglada M and Mazo A.
Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer.
BIOCHEMICAL PHARMACOLOGY . 76(3): 322-329. Nº de citas: 42
-
Pastor-Anglada M, Cano-Soldado P, Errasti-Murugarren E and Casado FJ.
SLC28 genes and concentrative nucleoside transporter (CNT) proteins.
Xenobiotica . 38(7-8): 972-994. Nº de citas: 67
-
Molina-Arcas M, Trigueros-Motos L, Casado FJ and Pastor-Anglada M.
Physiological and pharmacological roles of nucleoside transporter proteins.
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS . 27(6): 769-778. Nº de citas: 36
-
Hubeek I, Giovannetti E, Broekhuizen AJ, Pastor-Anglada M, Kaspers GJ and Peters GJ.
Immunocytochemical detection of hENT1 and hCNT1 in normal tissues, lung cancer cell lines, and NSCLC patient samples.
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS . 27(6): 787-793. Nº de citas: 7
-
Puebla C, Farías M, González M, Vecchiola A, Aguayo C, Krause B, Pastor-Anglada M, Casanello P and Sobrevia L.
High D-glucose reduces SLC29A1 promoter activity and adenosine transport involving specific protein 1 in human umbilical vein endothelium.
J CELL PHYSIOL . 215(3): 645-656. Nº de citas: 25
-
Minuesa G, Purcet S, Erkizia I, Molina-Arcas M, Bofill M, Izquierdo-Useros N, Casado FJ, Clotet B, Pastor-Anglada M and Martinez-Picado J.
Expression and functionality of anti-human immunodeficiency virus and anticancer drug uptake transporters in immune cells.
J PHARMACOL EXP THER . 324(2): 558-567. Nº de citas: 55
-
Errasti-Murugarren E, Cano-Soldado P, Pastor-Anglada M and Casado FJ.
Functional characterization of a nucleoside-derived drug transporter variant (hCNT3C602R) showing altered sodium-binding capacity.
MOLECULAR PHARMACOLOGY . 73(2): 379-386. Nº de citas: 28
-
Cano-Soldado P, Molina-Arcas M, Algueró B, Larráyoz I, Lostao MP, Grandas A, Casado FJ and Pastor-Anglada M.
Compensatory effects of the human nucleoside transporters on the response to nucleoside-derived drugs in breast cancer MCF7 cells.
BIOCHEMICAL PHARMACOLOGY . 75(3): 639-648. Nº de citas: 24
-
Govindarajan R, Bakken AH, Hudkins KL, Lai Y, Casado FJ, Pastor-Anglada M, Tse CM, Hayashi J and Unadkat JD.
In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placenta.
AM J PHYSIOL-REG I . 293(5): . Nº de citas: 122